These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 2906500)
1. Chronic uridine treatment reduces the level of [3H]spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours. Farabegoli C; Merlo Pich E; Cimino M; Agnati LF; Fuxe K Acta Physiol Scand; 1988 Feb; 132(2):209-16. PubMed ID: 2906500 [TBL] [Abstract][Full Text] [Related]
2. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats. Lévesque D; Di Paolo T Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586 [TBL] [Abstract][Full Text] [Related]
3. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Hamblin MW; Creese I Life Sci; 1983 May; 32(19):2247-55. PubMed ID: 6133202 [TBL] [Abstract][Full Text] [Related]
4. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study. Morissette M; Lévesque D; Di Paolo T Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544 [TBL] [Abstract][Full Text] [Related]
5. Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade. Henry JM; Roth GS Life Sci; 1984 Aug; 35(8):899-904. PubMed ID: 6482680 [TBL] [Abstract][Full Text] [Related]
6. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. Meller E; Bohmaker K; Goldstein M; Friedhoff AJ J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276 [TBL] [Abstract][Full Text] [Related]
7. Analysis of [3H]spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum. Fuxe K; Meller E; Goldstein M; Benfenati F; Agnati LF Neurosci Lett; 1986 Feb; 64(2):163-8. PubMed ID: 3960398 [TBL] [Abstract][Full Text] [Related]
8. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. Xu SX; Hatada Y; Black LE; Creese I; Sibley DR J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530 [TBL] [Abstract][Full Text] [Related]
9. Effect of aging on striatal dopamine receptor subtype recovery following N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline blockade and relation to motor function in Wistar rats. Henry JM; Joseph JA; Kochman K; Roth GS Brain Res; 1987 Aug; 418(2):334-42. PubMed ID: 2960421 [TBL] [Abstract][Full Text] [Related]
11. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine. Burger LY; Martin-Iverson MT Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985 [TBL] [Abstract][Full Text] [Related]
12. Dopamine receptor turnover rates in rat striatum are age-dependent. Leff SE; Gariano R; Creese I Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3910-4. PubMed ID: 6587399 [TBL] [Abstract][Full Text] [Related]
13. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease. Bennett JP; Wooten GF Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090 [TBL] [Abstract][Full Text] [Related]
14. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms. Norman AB; Battaglia G; Creese I J Neurosci; 1987 May; 7(5):1484-91. PubMed ID: 2952771 [TBL] [Abstract][Full Text] [Related]
15. Estimation of the apparent affinity of the striatal dopamine receptors for the radioligand[3H]spiperone [( 3H]spiroperidol). Hruska RE J Neurosci Res; 1984; 12(4):571-81. PubMed ID: 6512888 [TBL] [Abstract][Full Text] [Related]
16. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734 [TBL] [Abstract][Full Text] [Related]
17. EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors. Nowak G; Arnt J; Hyttel J Eur J Pharmacol; 1988 Aug; 153(2-3):309-11. PubMed ID: 3053212 [TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. Hess EJ; Norman AB; Creese I J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912 [TBL] [Abstract][Full Text] [Related]
19. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum. Zahniser NR; Dubocovich ML J Pharmacol Exp Ther; 1983 Dec; 227(3):592-9. PubMed ID: 6655559 [TBL] [Abstract][Full Text] [Related]
20. In vivo partial inactivation of dopamine D1 receptors induces hypersensitivity of cortical dopamine-sensitive adenylate cyclase: permissive role of alpha 1-adrenergic receptors. Trovero F; Hervé D; Blanc G; Glowinski J; Tassin JP J Neurochem; 1992 Jul; 59(1):331-7. PubMed ID: 1351927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]